Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC

Video

Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.

Related Videos
Kathryn Beckermann, MD, PhD
Arlene O. Siefker-Radtke, MD
Robert Wang, MD, of Fox Chase Cancer Center
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Roger Li, MD, of Moffitt Cancer Center
Joshua J. Meeks, MD, PhD, of Northwestern University Feinberg School of Medicine
Neal Shore, MD, FACS, of GenesisCare USA and Carolina Urologic Research Center
Jaime R. Merchán, MD
Mark D. Tyson, II, MD, MPH
Related Content
Oluwaseun Orikogbo, MD

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

May 6th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Antoni Vilaseca Cabo, MD, of Hospital Clínic de Barcelona

TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer

May 5th 2024
Article
Terence Friedlander, MD

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

April 24th 2023
Podcast
William C. Huang, MD, of NYU Grossman School of Medicine

UGN-102 With/Without TURBT Produces Similar DOR and DFS in Newly Diagnosed and Recurrent NMIBC

May 5th 2024
Article
Seth P. Lerner, MD

Extended Lymphadenectomy Shows No DFS, OS Benefit During Radical Cystectomy in Urothelial Cancer

May 3rd 2024
Article